RT Journal Article
SR Electronic
T1 Cohort profile: the Nordic Antireflux Surgery Cohort (NordASCo)
JF BMJ Open
JO BMJ Open
FD British Medical Journal Publishing Group
SP e016505
DO 10.1136/bmjopen-2017-016505
VO 7
IS 6
A1 John Maret-Ouda
A1 Karl Wahlin
A1 Miia Artama
A1 Nele Brusselaers
A1 Martti Färkkilä
A1 Elsebeth Lynge
A1 Fredrik Mattsson
A1 Eero Pukkala
A1 Pål Romundstad
A1 Laufey Tryggvadóttir
A1 My von Euler-Chelpin
A1 Jesper Lagergren
YR 2017
UL http://bmjopen.bmj.com/content/7/6/e016505.abstract
AB Purpose To describe a newly created all-Nordic cohort of patients with gastro-oesophageal reflux disease (GORD), entitled the Nordic Antireflux Surgery Cohort (NordASCo), which will be used to compare participants having undergone antireflux surgery with those who have not regarding risk of cancers, other diseases and mortality.Participants Included were individuals with a GORD diagnosis recorded in any of the nationwide patient registries in the Nordic countries (Denmark, Finland, Iceland, Norway and Sweden) in 1964–2014 (with various start and end years in different countries). Data regarding cancer, other diseases and mortality were retrieved from the nationwide registries for cancer, patients and causes of death, respectively.Findings to date The NordASCo includes 945 153 individuals with a diagnosis of GORD. Of these, 48 433 (5.1%) have undergone primary antireflux surgery. Median age at primary antireflux surgery ranged from 47 to 52 years in the different countries. The coding practices of GORD seem to have differed between the Nordic countries.Future plans The NordASCo will initially be used to analyse the risk of developing known or potential GORD-related cancers, that is, tumours of the oesophagus, stomach, larynx, pharynx and lung, and to evaluate the mortality in the short-term and long-term perspectives. Additionally, the cohort will be used to evaluate the risk of non-malignant respiratory conditions that might be caused by aspiration of gastric contents.